v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Mar. 31, 2026
Accounting Policies [Abstract]  
SCHEDULE OF EQUITY INVESTMENTS

The following summarizes the aggregate cost and fair value of the Company’s equity securities as of March 31, 2026, and 2025:

 

   For the Years Ending March 31, 
   2026   2025 
Cost Basis  $2,317,158    1,011,099 
Unrealized loss   (957,118)   (365,661)
Equity securities - Fair value  $1,360,040    645,438 
SCHEDULE OF DISAGGREGATED REVENUE

The Company’s disaggregated revenue by category is as follows:

  

       
   For the Years Ending March 31, 
   2026   2025 
         
Sale of pharmaceutical products and medical consultations  $32,908,881   $30,027,373 
Shipping and handling   2,485,908    3,090,251 
Other   300,825    - 
Total revenue, net  $35,695,614   $33,117,624 

SCHEDULE OF ACCOUNTS RECEIVABLE
       
   As of March 31, 
   2026   2025 
Accounts Receivables, Net  $356,054   $129,064